https://www.selleckchem.com/pr....oducts/Nicotinamide(
443). Moreover, chemotherapy improved survival for patients with resected PDAC in the median-risk (p less then 0.001) and high-risk (p less then 0.001) groups. Conclusions our research constructed a new risk-scoring system based on survival nomogram to screen low-risk PDAC patients after pancreatectomy and confirmed that those can avoid enduring side effects caused by chemotherapy without affecting the survival time.Introduction Biopsy is essential for some patients with suspected distant metastasis, so we aim to figur
Curtir
Comentario
Compartilhar
